Artwork

Indhold leveret af Labiotech. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Labiotech eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
Player FM - Podcast-app
Gå offline med appen Player FM !

BioSenic developing severe knee osteoarthritis treatment

31:43
 
Del
 

Manage episode 398840056 series 3361449
Indhold leveret af Labiotech. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Labiotech eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

BioSenic, a Belgian clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, will share data on its late-clinical asset JTA-004 at the Osteoarthritis Research Society International (OARSI) World Congress 2024 in Vienna, Austria.

The post hoc analysis of a phase 3 study found that a single injection of JTA-004 was safe and efficacious for patients with a newly characterized severe inflammatory subtype of knee osteoarthritis (OA).

This week on the podcast, we talk about the treatment with BioSenic chief scientific officer and chief operating officer, Dr Carole Nicco.

00:52-03:19: About BioSenic
03:19-07:34: What is osteoarthritis?
07:34-11:45: What is ALLOB?
11:45-15:03: What is JTA-004?
15:04-17:14: What will you be presenting at the OARSI event?
17:14-20:20: How useful is attending events for BioSenic?
20:20-21:04: How often will JTA-004 need to be administered?
21:04-24:08: Are other companies working on osteoarthritis?
24:08-26:26: What stage are your arsenic trioxide trails at?
26:26-29:50: Will this be useful in treating other autoimmune diseases?
29:50-31:08: What are the next steps?

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

  continue reading

Kapitler

1. BioSenic developing severe knee osteoarthritis treatment (00:00:00)

2. About BioSenic (00:00:52)

3. What is osteoarthritis? (00:03:19)

4. What is ALLOB? (00:07:34)

5. What is JTA-004? (00:11:45)

6. What will you be presenting at the OARSI event? (00:15:04)

7. How useful is attending events for BioSenic?
 (00:17:14)

8. How often will JTA-004 need to be administered? (00:20:20)

9. Are other companies working on osteoarthritis?
 (00:21:04)

10. What stage are your arsenic trioxide trails at?
 (00:24:08)

11. Will this be useful in treating other autoimmune diseases?
 (00:26:26)

12. What are the next steps? (00:29:50)

103 episoder

Artwork
iconDel
 
Manage episode 398840056 series 3361449
Indhold leveret af Labiotech. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Labiotech eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

BioSenic, a Belgian clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, will share data on its late-clinical asset JTA-004 at the Osteoarthritis Research Society International (OARSI) World Congress 2024 in Vienna, Austria.

The post hoc analysis of a phase 3 study found that a single injection of JTA-004 was safe and efficacious for patients with a newly characterized severe inflammatory subtype of knee osteoarthritis (OA).

This week on the podcast, we talk about the treatment with BioSenic chief scientific officer and chief operating officer, Dr Carole Nicco.

00:52-03:19: About BioSenic
03:19-07:34: What is osteoarthritis?
07:34-11:45: What is ALLOB?
11:45-15:03: What is JTA-004?
15:04-17:14: What will you be presenting at the OARSI event?
17:14-20:20: How useful is attending events for BioSenic?
20:20-21:04: How often will JTA-004 need to be administered?
21:04-24:08: Are other companies working on osteoarthritis?
24:08-26:26: What stage are your arsenic trioxide trails at?
26:26-29:50: Will this be useful in treating other autoimmune diseases?
29:50-31:08: What are the next steps?

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

  continue reading

Kapitler

1. BioSenic developing severe knee osteoarthritis treatment (00:00:00)

2. About BioSenic (00:00:52)

3. What is osteoarthritis? (00:03:19)

4. What is ALLOB? (00:07:34)

5. What is JTA-004? (00:11:45)

6. What will you be presenting at the OARSI event? (00:15:04)

7. How useful is attending events for BioSenic?
 (00:17:14)

8. How often will JTA-004 need to be administered? (00:20:20)

9. Are other companies working on osteoarthritis?
 (00:21:04)

10. What stage are your arsenic trioxide trails at?
 (00:24:08)

11. Will this be useful in treating other autoimmune diseases?
 (00:26:26)

12. What are the next steps? (00:29:50)

103 episoder

सभी एपिसोड

×
 
Loading …

Velkommen til Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Hurtig referencevejledning